|By Marketwired .||
|October 29, 2013 06:59 PM EDT||
AURORA, ON -- (Marketwired) -- 10/29/13 -- Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the year ended July 31, 2013.
The following are selected highlights during the 2013 fiscal year and subsequent to year-end:
- Announced receipt, on October 28, 2013, of subscription agreements for net proceeds in excess of $4,600,000. The terms of the private placement are for the purchase of common shares at $1.15 per share and include one warrant per share at an exercise price of $1.61 and have an expiry of five years from the date of issue. The completion of the private placement is subject to approval by the Toronto Stock Exchange;
- Completed first patient enrollment and dose administration in addition to recently completing an interim review of data collected for the first four cohorts in the Company's ongoing European Phase I/II clinical study of L-DOS47 in Poland. On October 15, 2013, the Company announced the completion of an interim review of data collected to date in this study. The data to date have shown that L-DOS47 was well-tolerated for all patients within all cohorts. Duration of treatment has increased with each dose escalation, including one patient that was dosed for approximately 18 weeks without disease progression. We remain on plan for the completion of the Phase I component of the trial by the summer of 2014 and a formal analysis of the data will be conducted following collection of all data at the completion of the study.
- Completed the sale of its Rivex Pharma division on January 25, 2013;
- Implemented changes to the board of directors resulted in the appointments of Sławomir Ludwikowski, Professor Sławomir Majewski and Mr. Stacy L. Wills;
- Announced its intention to change the Company's auditors from KPMG LLP to BDO Canada LLP, effective following the completion of the Company's fiscal 2013 audit by KPMG LLP, with a transition period that commenced on June 21, 2013;
- Established Helix Polska sp.z o.o., further strengthening Canadian-Polish relationships and scientific collaboration which began in 2005, when Polish investors first became shareholders of the Company;
- Terminated the material transfer and license agreement with Merck & Co. Inc. for the Company's Topical Interferon Alpha-2b drug development program and in addition closed the Saskatoon laboratory. The Company has now limited ongoing activities relating to its Tropical Interferon Alpha-2b to sourcing and qualifying alternative interferon alpha-2b raw material samples, and finding suitable strategic partner(s) who would be willing to license or acquire the product and support the remaining development costs through to commercial launch.
The Company recorded a net loss and total comprehensive loss of $1,545,000 ($0.02 loss per common share) and $17,423,000 ($0.26 loss per common share) for the fiscal years ended 2013 and 2012, respectively.
The net loss and comprehensive loss of $1,545,000 for the fiscal year ended 2013 includes a gain on sale from discontinued operations totaling $6,019,000 (2012 - $nil) and net income from discontinued operations totaling $630,000 (2012 - $1,431,000). On January 25, 2013, the Company announced the sale of its distribution business in Canada. In fiscal 2012 the Company realized a one-time charge of $6,536,000 (2013 - $nil) related to Special Committee and Settlement expenditures in connection with the 2012 AGM.
Excluding the gain on sale and the net income and total comprehensive income from discontinued operations, the Company realized a net loss and total comprehensive loss from continuing operations of $8,194,000 ($0.12 loss per common share) and $18,854,000 ($0.28 loss per common share) for the fiscal years ended 2013 and 2012, respectively.
Research and development
Research and development costs for fiscal 2013 and 2012 totalled $5,032,000 and $7,450,000, respectively, with the bulk of the research and development costs represented by L-DOS47, Topical Interferon Alpha-2b and Corporate research and development initiatives.
L-DOS47 research and development expenses for fiscal 2013 and 2012 totalled $2,771,000 and $3,581,000, respectively. L-DOS47 research and development expenditures mainly reflect expenditures associated with the ongoing European Phase I/II clinical study in Poland.
Topical Interferon Alpha-2b research and development expenses for fiscal 2013 and 2012 totalled $774,000 and $1,631,000, respectively. Beginning in June 2012, the Company initiated a downsizing of the staff in the Saskatoon laboratory which ultimately resulted in the close of the facility in November 2012. The Company has now limited ongoing activities relating to its Tropical Interferon Alpha-2b to sourcing and qualifying alternative interferon alpha-2b raw material samples, strengthening the BiPhasix patent portfolio and finding suitable strategic partner(s) who would be willing to license or acquire the product and support the remaining development costs through to commercial launch.
The Company also incurs corporate research and development expenses. Corporate research and development expenses totalled $1,081,000 and $1,407,000 respectively for the fiscal periods ended July 31, 2013 and 2012. The lower expenses can be attributed to a reduction in payroll expense associated with headcount reductions of corporate research and development employees in fiscal 2012 in addition to a reduction in travel, consulting and insurance related expenses.
Operating, general and administration
Operating, general and administration expenses for the fiscal years ended 2013 and 2012 totalled $3,196,000 and $4,580,000, respectively and represents a decrease of $1,384,000 (30.2%) when compared to fiscal 2012. Lower operating, general and administration expenses are the result of cost cutting measures by the Company, which include reductions related to lower legal and audit fees as a result of the Company having voluntarily surrendered its listing on the NYSE-MKT exchange in the United States, lower stock-based compensation expenses, reduced headcount and investor relations outsourcing activities.
Special committee and settlement agreement
All expenses relating to the Company's contested annual general meeting of shareholders in January 2012 and the related activities of the special committee and settlement agreement were incurred during fiscal 2012.
LIQUIDITY AND CAPITAL RESOURCES
The Company's cash reserves of $4,493,000 as at July 31, 2013 are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor are they sufficient to see the current research and development initiates through to completion. To the extent that the Company does not believe it has sufficient liquidity to meet its current obligations, management considers securing additional funds, primarily through the issuance of equity securities of the Company, to be of the utmost importance.
The Company's consolidated fiscal 2013 and 2012 financial statements are summarized below.
Consolidated Statements of Net Loss and Comprehensive Loss (thousand $, except for per share data) 2013 2012 --------- --------- Expenses: Research and development 5,032 7,450 Operating, general & administration 3,196 4,580 Special committee & settlement agreement - 6,536 Loss (gain) on disposal and impairment on property, plant and equipment (18) 320 --------- --------- Results from operating activities before finance items (8,210) (18,886) Finance items 16 32 --------- --------- Loss and total comprehensive lossfrom continuing operations (8,194) (18,854) Net income and total comprehensive income from discontinued operations 630 1,431 Gain fro msale of discontinued operations 6,019 - --------- --------- Net loss and total comprehensive loss (1,545) (17,423) ========= ========= Loss per share from continuing operations * $ (0.12) $ (0.28) Income per share from discontinued operations * $ 0.01 $ 0.02 Gain per share from sale of discontinued operations * $ 0.09 $ - Total loss per common share * $ (0.02) $ (0.26) * Figures are for both basic and fully diluted
Consolidated Statements of Cash Flows (thousand $) 2013 2012 --------- --------- Cash provided by (used in): Net loss and total comprehensive loss (8,194) (18,854) Items not involving cash: Depreciation of property, plant and equipment 396 699 Deferred lease credit (25) (25) Stock-based compensation 241 1,347 Stock-based consideration - 69 Foreign exchange loss 9 76 Loss on disposal and impairment on property, plant and equipment (18) 320 --------- --------- (7,591) (16,368) Changes in non-cash working capital (223) 828 --------- --------- Operating activities (7,814) (15,540) Financing activities - 43 Investing activities (6) (37) Effect of exchange rate changes on cash (9) (76) --------- --------- Net decrease in cash from continuing operations (7,829) (15,610) Net increase in cash from discontinued operations 7,460 1,428 Cash beginning of the year 4,862 19,044 --------- --------- Cash end of the year 4,493 4,862 ========= ========= Consolidated Statement of Financial Position (thousand $) 2013 2012 ---------- ---------- Non current assets 677 1,493 Current assets: Prepaids 139 107 Inventory - 421 Accounts receivable 559 733 Cash 4,493 4,862 ---------- ---------- 5,191 6,123 ---------- ---------- Total assets 5,868 7,616 ========== ========== Shareholders' equity 4,920 6,224 Non current liabilities - 23 Current liabilities: Deferred lease credit 23 25 Accrued liabilities 621 694 Accounts payable 304 650 ---------- ---------- 948 1,369 ---------- ---------- Total liabilities & shareholders equity 5,868 7,616 ========== ==========
The Company's complete 2013 Consolidated Financial Statements, Management's Discussion and Analysis and Annual Information Form are being filed today with Canadian securities regulatory authorities and will be available at www.sedar.com, as well as on the Company's website at www.helixbiopharma.com. Shareholders have the ability to receive a hard copy of the Company's complete audited financial statements free of charge upon request.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".
Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates; statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the focus of the Company on its two drug candidates, L-DOS47 and Topical Interferon Alpha-2b (cervical lesions indication) and other information in future periods.
Forward-looking statements include, without limitation, statements concerning (i) the Company's ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company's growth and future prospects being dependent on the success of one or both of L-DOS47 and Topical Interferon Alpha-2b; (iii) the Company's priority continuing to be L-DOS47; (iv) the Company's development programs for Topical Interferon Alpha-2b, DOS47 and L-DOS47, including but not limited to, extension of the drug candidates to other indications and the identification and development of further tumour-targeting antibodies for DOS47; (v) the Company's Polish Phase I/II clinical trials for L-DOS47; (vi) future expenditures, insufficiency of the Company's current cash resources and the need for financing and cost-cutting and/or cost-deferral measures; (vii) future financing requirements, the seeking of additional funding and anticipated future operating losses; and (viii) the acceptance of the private placement by the Toronto Stock Exchange, the closing of the private placement and the expected amount of the gross proceeds and the net proceeds to be received in connection with the private placement. Forward-looking statements can further be identified by the use of forward-looking terminology such as "2013", "2014", ongoing" or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", "would", or "should" occur or be achieved, or comparable terminology referring to future events or results.
Forward-looking statements are statements about the future and are inherently uncertain, and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release, including, but not limited to, the safety and efficacy of L-DOS47 and Topical Interferon Alpha-2b (low-grade cervical lesions); that sufficient financing will be obtained in a timely manner to allow the Company to continue operations; the timely provision of services and supplies, including Interferon alpha-2b raw materials, or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; the timely receipt of required regulatory approvals and strategic partner support; and the acceptance of the private placement by the Toronto Stock Exchange, the closing of the private placement and the expected amount of the net proceeds to be received in connection with the private placement.
The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation, the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all (including that the Toronto Stock Exchange may not accept the private placement and/or that the private placement may not close or that the actual amount of the net proceeds may be lower than anticipated), and that clinical trials may not commence or complete within anticipated timelines or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development or distribution activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in Helix's Annual Report, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed under Helix's profile on SEDAR at www.sedar.com from time to time at. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.
Helix BioPharma Corp.
Tel: 905 841-2300
Email: [email protected]
SYS-CON Events announced today that Agema Systems will exhibit at the 17th International Cloud Expo®, which will take place on November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Agema Systems is the leading provider of critical white-box rack solutions to data centers through the major integrators and value added distribution channels.
Oct. 4, 2015 03:30 AM EDT Reads: 550
Data loss happens, even in the cloud. In fact, if your company has adopted a cloud application in the past three years, data loss has probably happened, whether you know it or not. In his session at 17th Cloud Expo, Bryan Forrester, Senior Vice President of Sales at eFolder, will present how common and costly cloud application data loss is and what measures you can take to protect your organization from data loss.
Oct. 4, 2015 03:00 AM EDT Reads: 415
The cloud has reached mainstream IT. Those 18.7 million data centers out there (server closets to corporate data centers to colocation deployments) are moving to the cloud. In his session at 17th Cloud Expo, Achim Weiss, CEO & co-founder of ProfitBricks, will share how two companies – one in the U.S. and one in Germany – are achieving their goals with cloud infrastructure. More than a case study, he will share the details of how they prioritized their cloud computing infrastructure deployments ...
Oct. 4, 2015 03:00 AM EDT Reads: 602
Interested in leveraging automation technologies and a cloud architecture to make developers more productive? Learn how PaaS can benefit your organization to help you streamline your application development, allow you to use existing infrastructure and improve operational efficiencies. Begin charting your path to PaaS with OpenShift Enterprise.
Oct. 4, 2015 02:15 AM EDT Reads: 270
Decisions about budgets and resources are often made without IT even having a seat at the table. As technologist we understand the value of DevOps - but do your business counterparts? If they don't, your DevOps initiatives could lose funding before they start. In her session at DevOps Summit, Jeanne Morain, Strategist / Author at iSpeak Cloud, LLC, will provide insights on how to bridge the gap between business and technology leaders. Attendees will learn prescriptive guidance on balancing wor...
Oct. 4, 2015 02:00 AM EDT Reads: 502
The modern software development landscape consists of best practices and tools that allow teams to deliver software in a near-continuous manner. By adopting a culture of automation, measurement and sharing, the time to ship code has been greatly reduced, allowing for shorter release cycles and quicker feedback from customers and users. Still, with all of these tools and methods, how can teams stay on top of what is taking place across their infrastructure and codebase? Hopping between services a...
Oct. 4, 2015 12:00 AM EDT Reads: 230
Organizations already struggle with the simple collection of data resulting from the proliferation of IoT, lacking the right infrastructure to manage it. They can't only rely on the cloud to collect and utilize this data because many applications still require dedicated infrastructure for security, redundancy, performance, etc. In his session at 17th Cloud Expo, Emil Sayegh, CEO of Codero Hosting, will discuss how in order to resolve the inherent issues, companies need to combine dedicated a...
Oct. 4, 2015 12:00 AM EDT Reads: 364
For almost two decades, businesses have discovered great opportunities to engage with customers and even expand revenue through digital systems, including web and mobile applications. Yet, even now, the conversation between the business and the technologists that deliver these systems is strained, in large part due to misaligned objectives. In his session at DevOps Summit, James Urquhart, Senior Vice President of Performance Analytics at SOASTA, Inc., will discuss how measuring user outcomes –...
Oct. 3, 2015 11:00 PM EDT Reads: 272
Clearly the way forward is to move to cloud be it bare metal, VMs or containers. One aspect of the current public clouds that is slowing this cloud migration is cloud lock-in. Every cloud vendor is trying to make it very difficult to move out once a customer has chosen their cloud. In his session at 17th Cloud Expo, Naveen Nimmu, CEO of Clouber, Inc., will advocate that making the inter-cloud migration as simple as changing airlines would help the entire industry to quickly adopt the cloud wit...
Oct. 3, 2015 09:00 PM EDT Reads: 344
While testing is often ignored when it comes to DevOps - it could be the most important aspect of achieving true DevOps success. Without rethinking automated testing from the ground-up, the entire DevOps productivity gain cannot be realized. Large tech companies build their own rapid test automation that runs in minutes across functional, performance, security and other tests. In his session at DevOps Summit, Kevin Surace, CEO of Appvance, will discuss how we learn from these real-world succe...
Oct. 3, 2015 06:00 PM EDT Reads: 292
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
Oct. 3, 2015 05:00 PM EDT Reads: 310
Apps and devices shouldn't stop working when there's limited or no network connectivity. Learn how to bring data stored in a cloud database to the edge of the network (and back again) whenever an Internet connection is available. In his session at 17th Cloud Expo, Bradley Holt, Developer Advocate at IBM Cloud Data Services, will demonstrate techniques for replicating cloud databases with devices in order to build offline-first mobile or Internet of Things (IoT) apps that can provide a better, ...
Oct. 3, 2015 05:00 PM EDT Reads: 315
“All our customers are looking at the cloud ecosystem as an important part of their overall product strategy. Some see it evolve as a multi-cloud / hybrid cloud strategy, while others are embracing all forms of cloud offerings like PaaS, IaaS and SaaS in their solutions,” noted Suhas Joshi, Vice President – Technology, at Harbinger Group, in this exclusive Q&A with Cloud Expo Conference Chair Roger Strukhoff.
Oct. 3, 2015 03:00 PM EDT Reads: 270
SYS-CON Events announced today that Cloud Raxak has been named “Media & Session Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Raxak Protect automates security compliance across private and public clouds. Using the SaaS tool or managed service, developers can deploy cloud apps quickly, cost-effectively, and without error.
Oct. 3, 2015 01:15 PM EDT Reads: 559
SYS-CON Events announced today that ProfitBricks, the provider of painless cloud infrastructure, will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. ProfitBricks is the IaaS provider that offers a painless cloud experience for all IT users, with no learning curve. ProfitBricks boasts flexible cloud servers and networking, an integrated Data Center Designer tool for visual control over the...
Oct. 3, 2015 01:00 PM EDT Reads: 641